Synthesis and structure–activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases
摘要:
Pyrrolo[3,4-c]carbazoles bearing solubilising basic side chains at the 8-position retain potent Weel and Chk1 inhibitory properties in isolated enzyme assays, and evidence of G2/M checkpoint abrogation in several cellular assays. Co-crystal structure studies confirm that the primary binding to the Weel enzyme is as described previously, with the C-8 side chains residing in an area of bulk tolerance. (C) 2007 Elsevier Ltd. All rights reserved.
DOI:
10.1016/j.bmcl.2007.12.046
作为产物:
描述:
8-(Benzyloxy)-4-(2-chlorophenyl)-9-methoxy-4,5,6,10c-tetrahydropyrrolo[3,4-c]carbazole-1,3(2H,3aH)-dione 在
manganese dioxide 作用下,
以gave the carbazole (162) (93%) as an orange powder, mp 260–264° C的产率得到8-(Benzyloxy)-4-(2-chlorophenyl)-9-methoxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione
Synthesis and structure–activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases
作者:Jeff B. Smaill、Ho H. Lee、Brian D. Palmer、Andrew M. Thompson、Christopher J. Squire、Edward N. Baker、R. John Booth、Alan Kraker、Ken Hook、William A. Denny
DOI:10.1016/j.bmcl.2007.12.046
日期:2008.2
Pyrrolo[3,4-c]carbazoles bearing solubilising basic side chains at the 8-position retain potent Weel and Chk1 inhibitory properties in isolated enzyme assays, and evidence of G2/M checkpoint abrogation in several cellular assays. Co-crystal structure studies confirm that the primary binding to the Weel enzyme is as described previously, with the C-8 side chains residing in an area of bulk tolerance. (C) 2007 Elsevier Ltd. All rights reserved.
Inhibitors of checkpoint kinases (Wee1 and Chk1)
申请人:Pfizer Inc
公开号:US07094798B1
公开(公告)日:2006-08-22
This invention relates to pyrrolocarbazole derivatives according formula I wherein R1, R2, R7, R8, R9, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1